Short Interest in Hypera S.A. (OTCMKTS:HYPMY) Expands By 33,554.8%

Hypera S.A. (OTCMKTS:HYPMYGet Free Report) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 2,086,600 shares, a growth of 33,554.8% from the September 30th total of 6,200 shares. Based on an average daily trading volume, of 2,231,900 shares, the short-interest ratio is presently 0.9 days.

Hypera Trading Up 0.4 %

Shares of HYPMY opened at $4.97 on Friday. Hypera has a twelve month low of $3.83 and a twelve month high of $7.90. The firm has a market capitalization of $3.15 billion, a P/E ratio of 8.45 and a beta of 1.04. The stock’s fifty day simple moving average is $5.08 and its 200 day simple moving average is $5.34.

Hypera (OTCMKTS:HYPMYGet Free Report) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.15 EPS for the quarter. The firm had revenue of $420.00 million during the quarter.

About Hypera

(Get Free Report)

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

Featured Stories

Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.